Technology | Stents Drug Eluting

November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience ...

Home November 09, 2017
Home
Videos | Hemodynamic Support Devices

A discussion with William W. O’Neill, M.D., medical director, Center for Structural Heart Disease, Henry Ford Hospital ...

Home November 09, 2017
Home
News | Interventional Radiology

November 8, 2017 — Physicians at UnityPoint Health Methodist, Peoria, Ill., are now offering fast, safe and accurate ...

Home November 08, 2017
Home
Videos | Structural Heart Occluders

John Rhodes, M.D., co-director of the adult congenital heart program, Medical University of South Carolina, is the ...

Home November 08, 2017
Home
Videos | Cath Lab

Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on ...

Home November 08, 2017
Home
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.
Feature | Stents

November 8, 2017 – New results from the HARMONEE Japan/U.S. Registration Trial, reported by in a first report ...

Home November 08, 2017
Home
News | FFR Technologies

Investigators in the FAVOR II China and FAVOR II Europe-Japan studies recently presented their results at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) annual conference, Oct. 29-Nov. 2 in Denver.

Home November 08, 2017
Home
News | Heart Valve Technology

Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut Transcatheter Aortic Valve Replacement (TAVR) Platform in intermediate-risk, severe, symptomatic, aortic stenosis patients. Outcomes from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial and the Evolut R FORWARD “real-world” study were presented at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting, Oct. 29-Nov. 2 in Denver, reinforcing the valve’s strong performance in healthier, more active patients.

Home November 08, 2017
Home
Videos | Heart Valve Technology

Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at ...

Home November 08, 2017
Home
Videos | Heart Valve Technology

Stephen Worthley, MB, BS, Ph.D., director of cardiac catheterization, University of Adelaide, Australia, presents the ...

Home November 08, 2017
Home
Videos | Stents Bioresorbable

A discussion with Ajay Kirtane, M.D., SM, director of the cardiac catheterization laboratories at New York-Presbyterian ...

Home November 07, 2017
Home
Harpoon Mitral Valve Repair System data reported at TCT 2017
Feature | Heart Valve Technology

November 7, 2017 – A new study has found that a pioneering device to repair heart valves is safe and effective, and can ...

Home November 07, 2017
Home
Videos | Heart Valve Technology

Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, explains the current state of ...

Home November 07, 2017
Home
News | Heart Valve Technology

November 7, 2017 — Medtronic plc recently presented positive data for its self-expanding Intrepid transcatheter mitral ...

Home November 07, 2017
Home
News | Heart Valve Technology

http://www.tctconference.comA new study has found that a pioneering device to repair heart valves is safe and effective, and can reduce the invasiveness and side effects of conventional mitral valve surgery. The Harpoon Mitral Valve Repair System (H-MVRS), an image-guided device based on technology developed at the University of Maryland School of Medicine (UMSOM), is deployed through a small opening between the ribs, and repairs the heart while it continues to beat. The research was presented at the Transcatheter Cardiovascular Therapeutics (TCT 2017) symposium, Oct. 29-Nov. 2 in Denver, and simultaneously published in the Journal of the American College of Cardiology (JACC).

Home November 07, 2017
Home
Subscribe Now